ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, ...

Telitacicept in combination with standard therapy was effective for the treatment of systemic lupus erythematosus through 52 weeks.

Activation of certain memory B cells may be driving systemic lupus erythematosus incidence in individuals who had ...

Cambridge: AstraZeneca has announced that Saphnelo (anifrolumab) has been approved in the European Union (EU) for ...

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...

LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...

The study protocol comprises dose-expansion and dose-escalation phases and aims to assess the efficacy and safety of QT-019B.

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE).

A recent review published in Current Molecular Pharmacology explores the therapeutic potential of melatonin in systemic lupus ...

Hydroxychloroquine (HCQ) doses of at least 400 mg/day provided better symptom relief for Taiwanese people with systemic lupus ...

AN understanding of the interrelations of pregnancy and systemic lupus erythematosus is of considerable clinical importance, particularly since the disease occurs most frequently in women during the ...